Company: BIAF
Filing Date: 2025-05-02
Form Type: S-1
Source: 0001641172-25-008170
Chunk: 176

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-05-02
Form: S-1
Chunk 176
---
arrants will be unregistered
securities and will be evidenced by a global certificate, which shall be deposited on behalf of the Company with the Warrant Agent. Our
transfer agent, VStock Transfer, LLC, will serve as the Warrant Agent.

Fundamental Transaction

In the event of a fundamental transaction, as described in the April 2025 Warrants and generally including any reorganization, recapitalization or reclassification of our Common Stock, the sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation or merger with or into another person, the acquisition of greater than 50% of our outstanding Common Stock, or any person or group becoming the beneficial owner of greater than 50% of the voting power represented by our outstanding Common Stock, the holders of the April 2025 Warrants will be entitled to receive upon exercise of the April 2025 Warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised the April 2025 Warrants immediately prior to such fundamental transaction. In addition, in the event of a fundamental transaction which is approved by our board of directors, the holders of the April 2025 Warrants have the right to require us or a successor entity to redeem the April 2025 Warrant for cash in the amount of the Black-Scholes Value (as defined in the warrant) of the unexercised portion of the warrant on the date of the consummation of the fundamental transaction. In the event of a fundamental transaction which is not in our control, including a fundamental transactionnot approved by our board of directors, the holders of the April 2025 Warrants have the right to require us or a successor entity to redeem the warrant for the consideration paid in the fundamental transaction in the amount of the Black-Scholes Value of the unexercised portion of the warrant on the date of the consummation of the fundamental transaction.

Amendments

The April 2025 Warrants may be modified or amended with the written consent of the holder of such warrant and us.

Pre-Funded Warrants

The following summary of certain terms and provisions of the Pre-Funded Warrants that are being issued hereby is not complete and is subject to, and qualified in its entirety by, the provisions of the Pre-Funded Warrant, the form of which will be filed as an exhibit to the registration statement of which this prospectus forms a part. Prospective investors should carefully review the terms and provisions